Lepu Bio-B (02157) disclosed the 2023 annual results announcement. The group achieved revenue of 2.25 during the reporting period...
According to the Zhitong Finance App, Lepu Bio-B (02157) disclosed the 2023 annual results announcement. The group achieved revenue of 225 million yuan (RMB, same below) during the reporting period, a sharp increase of 1347.2% over the previous year. Gross profit was 197 million yuan, a year-on-year increase of 1352.6%.
License revenue from business development activities: During the reporting period, the group achieved total revenue of approximately $124 million. This amount relates to the licensing agreement between KYM (a joint venture formed by the company and Connoia) and AstraZeneca on February 23, 2023 for the development and commercialization of CMG901. According to the license agreement, the company has collected about 110 million yuan from KYM as license revenue. The remaining revenue comes from AstraZeneca (relating to the provision of services and pharmaceutical products).
Po Yoo-heng(Pritrizumab injections) Commercial revenue: During the reporting period, Puyouheng(Pritrizumab injection) achieved sales revenue of approximately 101 million yuan.